Peter Rumore
Rheumatology · Smithtown, NYNPI 1245226109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 570 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,727 and has fallen 50.8% since, to $1,835 in 2023.
Across 570 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Johnson & Johnson$1K
- Pfizer$956
- UCB, Inc.$751
- Lilly USA, LLC$712
- plus $4K from 23 others
Across 13 payments — averaging $6111.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$79K
What the payments were for
- Food & beverage$11,84699%
- Education$1651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $2,411 |
| Amgen(2 entities) | 94 | $2,394 |
| Johnson & Johnson(2 entities) | 51 | $1,071 |
| Pfizer | 73 | $956 |
| UCB, Inc. | 44 | $751 |
| Lilly USA, LLC | 38 | $712 |
| Genentech USA, Inc. | 29 | $531 |
| GSK | 23 | $499 |
| AstraZeneca | 17 | $416 |
| Novartis | 24 | $355 |
| Mallinckrodt Enterprises LLC | 8 | $328 |
| Aurinia Pharma U.S., Inc. | 15 | $295 |
| Radius Health, Inc. | 16 | $289 |
| Regeneron Healthcare Solutions, Inc. | 6 | $170 |
| Boehringer Ingelheim | 6 | $151 |
| Ferring Pharmaceuticals Inc. | 6 | $121 |
| Pacira Therapeutics, Inc. | 3 | $104 |
| Antares Pharma, Inc. | 4 | $87 |
| Medexus Pharma, Inc. | 5 | $72 |
| Sobi, Inc | 2 | $51 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $47 |
| Bristol Myers Squibb | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Fidia Pharma USA Inc. | 2 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| GRT US Holding, Inc. | 1 | $20 |
| Sandoz | 1 | $14 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,011 in reported general payments places this provider in the 75th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 38 | $1,043 |
| MethotrexateMethotrexate Sodium | 12 | $304 |
| Prednisone | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Smithtown
- Howard BlumsteinSmithtown$56K
- Paul SchulmanSmithtown$54K
- Daniel Torres LeyvaSmithtown$47K
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.